Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

HK Type 4 license through Ballingal Investment Advisors Ltd. ("BIA" or "BIAL")

BACKGROUND
I have 20+yrs experience in Asia doing alternative strategies (i.e. non-delta1 non long-only) in fixed income, equity derivatives, and activist/catalyst/event-driven and long-short equity strategies with most of that time spent managing money. 

4 years in fixed income macro, 8 years running internal hedge fund and 4yrs investment banking at Citi in Japan, 3 years running an Asia multi-strat portfolio at a hedge fund, 4+yrs as an independent special situations analyst.

Pan-Asia Catalysts/Events

[Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn

Medical Data Vision (3902) - SBI Upping Their Stake AGAIN In The Market

Medical Data Vision (3902) - SBI Upping Their Stake Means Opportunity

Quiddity Advisors

Event-Driven

<ul>
<li>Over the weekend the Nikkei reported that Nippon Life would bid ¥60bn for <a href="https://www.smartkarma.com/entities/medical-data-vision-co-ltd" target="_blank" data-smartkarma-citation="entities:8367:1" rel="noopener">Medical Data Vision (3902 JP)</a>. At one price per share, that meant ¥1,585.  </li>
<li>There is a deemed dividend treatment buyback for SBI at ¥1,189 which means they will end up with a capital loss (their in-price is ¥1,630) but they'll offset that.</li>
<li>This is the biggest win for minorities in a long while. Be happy.</li>
</ul>


Over the weekend the Nikkei reported that Nippon Life would bid ¥60bn for Medical Data Vision (3902 JP). At one price per share, that meant ¥1,585.  
There is a deemed dividend treatment buyback for SBI at ¥1,189 which means they will end up with a capital loss (their in-price is ¥1,630) but they'll offset that.
This is the biggest win for minorities in a long while. Be happy.


[Japan M&A] Nippon Life Shoots the Lights Out with a Bid at ¥1,693